T5O Stock Overview
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies.
Price History & Performance
|Historical stock prices|
|Current Share Price||€3.89|
|52 Week High||€18.35|
|52 Week Low||€3.40|
|1 Month Change||-5.12%|
|3 Month Change||6.58%|
|1 Year Change||-78.15%|
|3 Year Change||-69.61%|
|5 Year Change||-70.46%|
|Change since IPO||-73.08%|
Recent News & Updates
Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
CytoTools AG (ETR:T5O): Are Analysts Optimistic?
With the business potentially at an important milestone, we thought we'd take a closer look at CytoTools AG's ( ETR:T5O...
|T5O||DE Biotechs||DE Market|
Return vs Industry: T5O underperformed the German Biotechs industry which returned -31.4% over the past year.
Return vs Market: T5O underperformed the German Market which returned -12.9% over the past year.
|T5O Average Weekly Movement||13.1%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||6.4%|
|10% most volatile stocks in DE Market||10.6%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: T5O is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: T5O's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company’s therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective.
CytoTools Fundamentals Summary
|T5O fundamental statistics|
Is T5O overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|T5O income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-7,836.80%|
How did T5O perform over the long term?See historical performance and comparison
Is CytoTools undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate T5O's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate T5O's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: T5O is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: T5O is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate T5O's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: T5O is good value based on its PB Ratio (0.7x) compared to the DE Biotechs industry average (1.5x).
How is CytoTools forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytoTools has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has CytoTools performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: T5O is currently unprofitable.
Growing Profit Margin: T5O is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: T5O is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare T5O's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: T5O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: T5O has a negative Return on Equity (-8.19%), as it is currently unprofitable.
How is CytoTools's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: T5O's short term assets (€855.5K) exceed its short term liabilities (€257.3K).
Long Term Liabilities: T5O's short term assets (€855.5K) exceed its long term liabilities (€2.6K).
Debt to Equity History and Analysis
Debt Level: T5O is debt free.
Reducing Debt: T5O had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if T5O has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if T5O has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is CytoTools's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate T5O's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate T5O's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if T5O's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if T5O's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as T5O has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Dr. Mark-André Freyberg co-founded CytoTools AG in 2000 and serves as Chief Executive Officer since 2000 and had been the Chairman of Management Board until September 30, 2021 and previously also served as...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
CytoTools AG's employee growth, exchange listings and data sources
- Name: CytoTools AG
- Ticker: T5O
- Exchange: XTRA
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €15.669m
- Shares outstanding: 4.03m
- Website: https://cytotools.de
Number of Employees
- CytoTools AG
- Klappacher Strasse 126
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.